Video

Dr. Basho on the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

Reva K. Basho, MD, discusses the integration of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Reva K. Basho, MD, assistant professor of medicine, co-director, Women’s Cancer Program, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, discusses the integration of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive breast cancer.

Following its FDA approval in December 2019, trastuzumab deruxtecan has become a standard third- or fourth-line therapy for patients with HER2-positive breast cancer, Basho says. When to sequence the agent is largely dependent on patient and physician preferences, Basho adds.

However, toxicity remains a concern with trastuzumab deruxtecan, particularly with regard to the risk of fatal interstitial lung disease (ILD), Basho explains. Other therapies that are available for later-line use in HER2-positive breast cancer are generally well tolerated with limited alopecia, Basho says. As such, safety needs to be considered when selecting trastuzumab deruxtecan for a patient, Basho concludes.


Related Videos
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center